Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Isoconazole→

Isoconazole Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
27523-40-6
Molecular formula
C18H14Cl4N2O
Molecular weight
416.1 g/mol
Drug class
Imidazole azole antifungalergosterol-biosynthesis inhibitor
Mechanism of action
Inhibits fungal lanosterol 14-alpha-demethylase, disrupting ergosterol synthesis and altering fungal cell-membrane structure and function.
Indications / reported uses
  • Topical treatment of superficial dermatophyte and yeast skin infections, including tinea pedis, tinea corporis and cutaneous candidiasis, where authorised
  • Vaginal formulations may be authorised for vulvovaginal candidiasis in selected markets; route-specific products are not interchangeable

Sources: NLM MeSH — Isoconazole · PubMed — Isoconazole antifungal pharmacology · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Isoconazole Environmental Risk Assessment (ERA) (the Isoconazole ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.